Mankind Pharma Gets Relief as CGST Appellate Authority Drops Rs 1.02 Cr Penalty
New Delhi: Mankind Pharma Limited has received an order from the Additional Commissioner, CGST (Appeals), Meerut, Uttar Pradesh, dropping a penalty of Rs 1,02,05,688 imposed under Section 74 of the Central Goods and Services Tax (CGST) Act, 2017, for the financial years 2017-18 to 2020-21.
In an intimation dated February 26, 2026, submitted to the stock exchanges under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company informed that it received the Order-in-Appeal on February 25, 2026.
The appeal order, dated January 28, 2026, pertains to the company’s challenge against the Order-in-Original dated December 27, 2024, passed by the Assistant Commissioner, Central Goods and Services Tax, Meerut, Uttar Pradesh.
As per the disclosure, the Order-in-Appeal No. MRT/CGST/000/APPL-MRT/573-576/2025-26 has set aside the demand of penalty amounting to Rs 1,02,05,688, which had been imposed in the earlier order under Section 74 of the CGST Act. The matter related to the assessment period covering four financial years from 2017-18 to 2020-21.
The company clarified in Annexure-I of its disclosure that there were no details of any specific violation or contravention committed or alleged to have been committed. It also stated that there is no quantifiable impact on the financial, operational or other activities of the listed entity pursuant to the appellate order.
Also Read: Mankind Pharma Reports 11.5% Revenue Growth in Q3 FY26
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.